Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
MCET > SEC Filings for MCET > Form 8-K on 25-Oct-2012All Recent SEC Filings

Show all filings for MULTICELL TECHNOLOGIES, INC.

Form 8-K for MULTICELL TECHNOLOGIES, INC.


25-Oct-2012

Entry into a Material Definitive Agreement


Item 1.01 Entry into a Material Definitive Agreement.

On October 23, 2012 Xenogenics Corporation (the "Purchaser"), a subsidiary of MultiCell Technologies, Inc. (the "Registrant"), entered into an Amendment No. 2 (the "Amendment No. 2") to Foreclosure Sale Agreement (the "Agreement") with Venture Lending & Leasing IV, Inc. ("VLL4"), Venture Lending & Leasing V, Inc. ("VLL5") and Silicon Valley Bank ("SVB"). VLL4, VLL5 and SVB are sometimes referred to hereinafter collectively as "Sellers".

The Sellers previously entered into the Agreement with the Purchaser on September 30, 2010. An Amendment No. 1 to Foreclosure Sale Agreement was executed on September 30, 2011 (the "Amendment No. 1"). The foregoing descriptions of the Agreement and the Amendment No. 1 are qualified in their entirety by reference to the full text of such Agreement and such Amendment No. 1, copies of which is filed as Exhibit 10.2 to the Registrant's Current Report on Form 8-K filed on October 20, 2010, and Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on October 6, 2011, and are hereby incorporated by reference herein.

Under the terms of Amendment No. 2 to Foreclosure Agreement, the deadlines for the achievement of certain milestones under the Agreement are extended. The deadline to restart manufacturing of the Generation 2 bio-absorbable stent device was extended to 24 months from the date of execution of Amendment No. 1; the deadline to initiate an animal study was extended to within 30 months from the date of execution of Amendment No. 1; the deadline to make a regulatory submission to support a human use clinical trial was extended to within 36 months from the date of execution of Amendment No. 1; the deadline to initiate a human use clinical trial was extended to within 48 months from the date of execution of Amendment No. 1; and the deadline to make a regulatory submission or equivalent for marketing approval for use in humans was extended to within 60 months from the date of execution of Amendment No. 1. The foregoing description of the Amendment No. 2 is qualified in its entirety by reference to the full text of such agreement, a copy of which is filed as Exhibit 10.1 hereto, and is hereby incorporated by reference herein.

Item 9.01 Exhibits

(d) Exhibits

10.1 Amendment No. 2 To Foreclosure Sale Agreement, dated as of October 23, 2012, by and among Venture Lending & Leasing IV, Inc., Venture Lending & Leasing V, Inc., Silicon Valley Bank and Xenogenics Corporation.

  Add MCET to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for MCET - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.